<PAPER>
  <mode2 name="11099637_arathi" hasDoc="yes" version="1258"/>
  <TITLE>
    <s sid="1">Effect of Trihalomethanes on Cell Proliferation and DNA Methylation in Female B6C3F1 Mouse Liver<CoreSc1 atype="GSC" type="Obj" conceptID="Obj1" novelty="None" advantage="None"/></s>
  </TITLE>
  <ABSTRACT>
    <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-1">
      <s sid="2">Trihalomethanes (chloroform, bromodichloromethane, chlorodibromomethane, and bromoform) are regulated organic contaminants in chlorinated drinking water.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac1" novelty="None" advantage="None"/></s>
      <s sid="3">In female B6C3F1 mouse liver, the 4 trihalomethanes have demonstrated carcinogenic activity when administered by oral gavage; however, chloroform was not carcinogenic when administered in drinking water.<CoreSc1 atype="GSC" type="Res" conceptID="Res1" novelty="None" advantage="None"/></s>
      <s sid="4">Female B6C3F1 mice were administered the trihalomethanes for 11 days by gavage at 2 dose levels or in the drinking water at &#8764;75% saturation.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/></s>
      <s sid="5">When administered by gavage, the trihalomethanes were toxic to the liver, increased the liver:body weight (bw) ratio, and increased the proliferating cell nuclear antigen-labeling index (PCNA-LI).<CoreSc1 atype="GSC" type="Res" conceptID="Res2" novelty="None" advantage="None"/></s>
      <s sid="6">Chloroform and bromodichloromethane were the most toxic, and they increased the liver:bw ratio the most, while bromoform and chloroform increased the PCNA-LI the most.<CoreSc1 atype="GSC" type="Res" conceptID="Res3" novelty="None" advantage="None"/></s>
      <s sid="7">When administered in drinking water, the toxicity of the trihalomethanes was similar to their low gavage-dose.<CoreSc1 atype="GSC" type="Res" conceptID="Res4" novelty="None" advantage="None"/></s>
      <s sid="8">Furthermore, only chloroform significantly increased the liver:bw ratio and bromoform and chloroform increased the PCNA-LI.<CoreSc1 atype="GSC" type="Res" conceptID="Res5" novelty="None" advantage="None"/></s>
      <s sid="9">Chloroform and bromodichloromethane decreased the level of 5-methylcytosine in hepatic DNA.<CoreSc1 atype="GSC" type="Res" conceptID="Res6" novelty="None" advantage="None"/></s>
      <s sid="10">Methylation in the promoter region of the c-myc gene was reduced by the trihalomethanes.<CoreSc1 atype="GSC" type="Res" conceptID="Res7" novelty="None" advantage="None"/></s>
      <s sid="11">Chloroform administered by gavage was more efficacious than given in drinking water; the efficacy of the other trihalomethanes did not differ for the 2 routes.<CoreSc1 atype="GSC" type="Res" conceptID="Res8" novelty="None" advantage="None"/></s>
      <s sid="12">Thus, in mouse liver, the trihalomethanes administered by gavage enhanced cell proliferation and decreased the methylation of the c-myc gene, consistent with their carcinogenic activity.<CoreSc1 atype="GSC" type="Con" conceptID="Con1" novelty="None" advantage="None"/></s>
      <s sid="13">Furthermore, the more modest toxicity, enhancement of cell proliferation, and decreased methylation induced by chloroform administered in drinking water correlated with its lack of carcinogenic activity.<CoreSc1 atype="GSC" type="Con" conceptID="Con2" novelty="None" advantage="None"/></s>
      <s sid="14">Hence, the activity of the trihalomethanes was dependent on the rate of delivery, i.e. rapid by oral gavage and more slowly in drinking water.<CoreSc1 atype="GSC" type="Con" conceptID="Con3" novelty="None" advantage="None"/></s>
    </p>
  </ABSTRACT>
  <BODY>
    <SEC>
      <TITLE/>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-2">
        <s sid="15">Trihalomethanes (THM), i.e., chloroform (CHCl<sub>3</sub>), bromodichloromethane (CHBrCl<sub>2</sub>), chlorodibromomethane (CHClBr<sub>2</sub>), and bromoform (CHBr<sub>3</sub>) are major organic by-products of drinking water chlorination, resulting from the reaction of chlorine with natural organic material and bromine in source waters (<xref class="xref-bibr" href="#ref-48" rid="xref-ref-48-1">Uden and Miller, 1983</xref>; <xref class="xref-bibr" href="#ref-8" rid="xref-ref-8-1">Coleman et al., 1984</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac2" novelty="None" advantage="None"/></s>
        <s sid="16">The discovery of these by-products in drinking water has raised questions about their health hazards (<xref class="xref-bibr" href="#ref-17" rid="xref-ref-17-1">Jolley et al., 1990</xref>, <xref class="xref-bibr" href="#ref-14" rid="xref-ref-14-1">IARC, 1991</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac3" novelty="None" advantage="None"/></s>
        <s sid="17">All four trihalomethanes, when administered by gavage, are carcinogenic in the livers of female B6C3F1 mice (<xref class="xref-bibr" href="#ref-27" rid="xref-ref-27-1">NCI, 1976</xref>; <xref class="xref-bibr" href="#ref-28" rid="xref-ref-28-1">NTP, 1985</xref>, <xref class="xref-bibr" href="#ref-29" rid="xref-ref-29-1">1987</xref>, <xref class="xref-bibr" href="#ref-30" rid="xref-ref-30-1">1989</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac4" novelty="None" advantage="None"/></s>
        <s sid="18">The carcinogenic activity of the trihalomethanes has been proposed to be mediated through a nongenotoxic mechanism based on their weak activity in mutagenicity and genotoxicity assays (Le Cureiux et al., 1995; <xref class="xref-bibr" href="#ref-40" rid="xref-ref-40-1">Reitz et al., 1990</xref>; <xref class="xref-bibr" href="#ref-42" rid="xref-ref-42-1">Rosenthal et al., 1987</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac5" novelty="None" advantage="None"/></s>
        <s sid="19">However, one trihalomethane, bromodichloromethane, has demonstrated mutagenic activity apparently though a glutathione (GSH) metabolite (<xref class="xref-bibr" href="#ref-33" rid="xref-ref-33-1">Pegram et al., 1997</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac6" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-3">
        <s sid="20">The route of administration appears to play a significant role in the dosimetry and metabolism of the trihalomethanes and consequently in their carcinogenic and toxic activity.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp1" novelty="None" advantage="None"/></s>
        <s sid="21">Although, chloroform was carcinogenic in mice when administered by gavage, it was not carcinogenic and did not promote liver cancer when administered in the drinking water (<xref class="xref-bibr" href="#ref-19" rid="xref-ref-19-1">Jorgenson, et al., 1985</xref>; <xref class="xref-bibr" href="#ref-20" rid="xref-ref-20-1">Klaunig et al., 1986</xref>; <xref class="xref-bibr" href="#ref-36" rid="xref-ref-36-1">Pereira et al., 1985</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac7" novelty="None" advantage="None"/></s>
        <s sid="22">Furthermore, cell proliferation was enhanced by chloroform administered by gavage but not given in drinking water (<xref class="xref-bibr" href="#ref-23" rid="xref-ref-23-1">Larson et al., 1994</xref>; <xref class="xref-bibr" href="#ref-34" rid="xref-ref-34-1">Pereira, 1994</xref>; <xref class="xref-bibr" href="#ref-35" rid="xref-ref-35-1">Pereira and Grothaus, 1997</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac8" novelty="None" advantage="None"/></s>
        <s sid="23">The trihalomethanes are metabolized to reactive dihalocarbonyl metabolites that react with nucleophilic compounds and macromolecules (<xref class="xref-bibr" href="#ref-1" rid="xref-ref-1-1">Ammann et al., 1998</xref>; <xref class="xref-bibr" href="#ref-26" rid="xref-ref-26-1">Lilly et al., 1997</xref>; <xref class="xref-bibr" href="#ref-31" rid="xref-ref-31-1">Pankow et al., 1997</xref>; <xref class="xref-bibr" href="#ref-38" rid="xref-ref-38-1">Pohl, 1977</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac9" novelty="None" advantage="None"/></s>
        <s sid="24">Thus, the dihalocarbonyl metabolite of chloroform, phosgene, binds glutathione (GSH) in what appears to be a detoxifying mechanism (<xref class="xref-bibr" href="#ref-15" rid="xref-ref-15-1">Ilett et al., 1973</xref>; <xref class="xref-bibr" href="#ref-37" rid="xref-ref-37-1">Pohl, 1979</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac10" novelty="None" advantage="None"/></s>
        <s sid="25">Administering the trihalomethanes as a bolus by gavage is expected to result in greater plasma and liver concentrations than when the same dose is delivered during the time the mice drink water.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp2" novelty="None" advantage="None"/></s>
        <s sid="26">Thus, administering the trihalomethanes by gavage could overwhelm the ability of the liver to detoxify them, resulting in toxicity, regenerative hyperplasia, and promotion of cancer.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp3" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-4">
        <s sid="27">Regulation of cell proliferation is a critical facet of carcinogenesis; consequently, one mechanism proposed for nongenotoxic mouse liver carcinogens, including the trihalomethanes, is the enhancement of cell proliferation (<xref class="xref-bibr" href="#ref-5" rid="xref-ref-5-1">Butterworth et al., 1992</xref>; <xref class="xref-bibr" href="#ref-12" rid="xref-ref-12-1">Goodman et al., 1991</xref>; <xref class="xref-bibr" href="#ref-41" rid="xref-ref-41-1">Roberts et al., 1997</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac11" novelty="None" advantage="None"/></s>
        <s sid="28">Decreased methylation of DNA and protooncogenes could result in decreased regulation of cell proliferation (<xref class="xref-bibr" href="#ref-9" rid="xref-ref-9-1">Counts and Goodman, 1995</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac12" novelty="None" advantage="None"/></s>
        <s sid="29">5-Methylcytosine (5-MeC) is a naturally occurring modification of eukaryotic DNA that plays a role in the control of gene expression (<xref class="xref-bibr" href="#ref-2" rid="xref-ref-2-1">Baylin et al., 1998</xref>; Kegelmeye et al., 1997; <xref class="xref-bibr" href="#ref-39" rid="xref-ref-39-1">Razin and Kafri, 1994</xref>; <xref class="xref-bibr" href="#ref-52" rid="xref-ref-52-1">Wolffe et al., 1999</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac13" novelty="None" advantage="None"/></s>
        <s sid="30">Decreased levels of 5-MeC in DNA and in specific genes are frequent early events in human and rodent tumors (<xref class="xref-bibr" href="#ref-2" rid="xref-ref-2-2">Baylin et al., 1998</xref>; <xref class="xref-bibr" href="#ref-3" rid="xref-ref-3-1">Bender et al., 1998</xref>; Bird et al., 1996; <xref class="xref-bibr" href="#ref-32" rid="xref-ref-32-1">Pascale et al., 1993</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac14" novelty="None" advantage="None"/></s>
        <s sid="31">In mouse liver, nongenotoxic carcinogens, including dichloroacetic acid (DCA), phenobarbital, trichloroacetic acid (TCA), and trichloroethylene, have been shown to decrease the methylation of DNA and protooncogenes (<xref class="xref-bibr" href="#ref-9" rid="xref-ref-9-2">Counts and Goodman, 1995</xref>; <xref class="xref-bibr" href="#ref-10" rid="xref-ref-10-1">Counts et al., 1996</xref>; <xref class="xref-bibr" href="#ref-44" rid="xref-ref-44-1">Tao et al., 1998</xref>, <xref class="xref-bibr" href="#ref-45" rid="xref-ref-45-1">1999</xref> Tao et al., 2000).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac15" novelty="None" advantage="None"/></s>
        <s sid="32">Thus, DNA hypomethylation has been proposed as a mechanism for nongenotoxic carcinogens and tumor promoters (<xref class="xref-bibr" href="#ref-9" rid="xref-ref-9-3">Counts and Goodman, 1995</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac16" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-5">
        <s sid="33">The protooncogene and cellular transcription factor, c-myc, plays a pivotal role in apoptosis, cell replication, and differentiation (<xref class="xref-bibr" href="#ref-7" rid="xref-ref-7-1">Christensen et al., 1999</xref>; <xref class="xref-bibr" href="#ref-13" rid="xref-ref-13-1">Holden et al., 1998</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac17" novelty="None" advantage="None"/></s>
        <s sid="34">The expression of c-myc is increased in the liver during enhanced cell proliferation (<xref class="xref-bibr" href="#ref-6" rid="xref-ref-6-1">Butterworth et al., 1994</xref>; <xref class="xref-bibr" href="#ref-11" rid="xref-ref-11-1">Fausto and Shank, 1983</xref>; <xref class="xref-bibr" href="#ref-43" rid="xref-ref-43-1">Sprankle et al., 1996</xref>; <xref class="xref-bibr" href="#ref-51" rid="xref-ref-51-1">Wainfan and Poirier, 1992</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac18" novelty="None" advantage="None"/></s>
        <s sid="35">Methylation of CpG sites in its promoter region regulates in part the expression of its mRNA (<xref class="xref-bibr" href="#ref-18" rid="xref-ref-18-1">Jones and Buckley, 1990</xref>; <xref class="xref-bibr" href="#ref-39" rid="xref-ref-39-2">Razin and Kafri, 1994</xref>; Wainfan and Poirer, 1992).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac19" novelty="None" advantage="None"/></s>
        <s sid="36">The methylation of the c-myc gene is decreased by a diet deficient in choline and methionine (Wainfan and Poirer, 1992) and by DCA, TCA, and trichloroethylene (<xref class="xref-bibr" href="#ref-45" rid="xref-ref-45-2">Tao et al., 1999</xref>Tao et al., 2000).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac20" novelty="None" advantage="None"/></s>
        <s sid="37">Thus, decreased methylation of the c-myc gene could be used as a biomarker for DNA hypomethylation induced by nongenotoxic carcinogens.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot1" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-6">
        <s sid="38">The studies reported here compared in mouse liver the ability of the trihalomethanes to induce toxicity, to increase cell proliferation, and to decrease the methylation of the c-myc protooncogene.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj2" novelty="None" advantage="None"/></s>
        <s sid="39">We also report a comparison of the activity of the trihalomethanes administered by oral gavage to their activity when administered in drinking water.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj3" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>MATERIALS AND METHODS</TITLE>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Chemicals and DNA probes.</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-7">
        <s sid="40">Bromodichloromethane, chlorodibromomethane, and bromoform were purchased from Aldrich Chemical Co., Inc. (Milwaukee, WI); chloroform, 3-3&#8242;-diaminobenzidine tablet set, monoclonal mouse anti-PCNA, proteinase K, and ribonuclease A type III-A were from Sigma Chemical Co. (St. Louis, MO); and TRIzol Reagent were from GIBCO BRL/Life Technologies, Inc. (Gaithersburg, MD).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp2" novelty="None" advantage="None"/></s>
        <s sid="41">Vectastain ABC kit, peroxidase mouse IgG PK-4002 was purchased from Vector Laboratories (Burlingame, CA).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp3" novelty="None" advantage="None"/></s>
        <s sid="42">Oligonucleotide probes for c-myc were obtained from Oncogene Research Products (Cambridge, MA).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp4" novelty="None" advantage="None"/></s>
        <s sid="43">Hpa II and Msp I were from New England BioLabs (Beverly, Ma).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp5" novelty="None" advantage="None"/></s>
        <s sid="44">Hybond&#8482;-N<sup>+</sup> nylon membranes, (&#945;-<sup>32</sup>P)-dCTP (6000 Ci/mmol), (&#947;-<sup>32</sup>P)-ATP (5000 Ci/mmol), enhanced chemiluminescence reagents and T<sub>4</sub> polynucleotide kinase were obtained from Amersham Corp. (Arlington Heights, IL).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp6" novelty="None" advantage="None"/></s>
        <s sid="45">Prime-a-Gene Labeling System was obtained from Promega Corp. (Madison, WI).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp7" novelty="None" advantage="None"/></s>
        <s sid="46">All other chemicals were electrophoresis and HPLC grade or the highest purity available.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp8" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Animals.</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-8">
        <s sid="47">VAF (viral antibody-free) 6-week old female B6C3F1 mice were purchased from Charles River Breeding Laboratory (Portage, MI) and maintained in our AAALAC accredited laboratory-animal facility.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp9" novelty="None" advantage="None"/></s>
        <s sid="48">The mice were housed in polycarbonate cages (4/cage) with stainless steel wire lids and absorbent corncob bedding (Andersons, Toledo, OH) in humidity and temperature controlled rooms with a 12-h light/dark cycle.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp10" novelty="None" advantage="None"/></s>
        <s sid="49">Deionized filtered tap water with/without the trihalomethanes and Purina Rodent Diet (J&amp;B Feed, Toledo, OH) were provided ad libitum.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp11" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Experimental design.</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-9">
        <s sid="50">At 7&#8211;8 weeks of age, the mice were weighed and randomly assigned to the different treatment groups (Table 1).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp12" novelty="None" advantage="None"/></s>
        <s sid="51">The mice then started to receive the trihalomethanes either in their drinking water for 11 consecutive days or by oral gavage in corn oil administered daily for 5 days, off for 2 days, and then daily again for 4 days.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp13" novelty="None" advantage="None"/></s>
        <s sid="52">The mice were sacrificed 24 h after the last gavage dose.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp14" novelty="None" advantage="None"/></s>
        <s sid="53">The dose levels of the trihalomethanes administered by gavage in corn oil were selected so that the high dose had been previously demonstrated to be carcinogenic in female B6C3F1 mice (<xref class="xref-bibr" href="#ref-27" rid="xref-ref-27-2">NCI, 1976</xref>; <xref class="xref-bibr" href="#ref-28" rid="xref-ref-28-2">NTP, 1985</xref>, <xref class="xref-bibr" href="#ref-29" rid="xref-ref-29-2">1987</xref>, <xref class="xref-bibr" href="#ref-30" rid="xref-ref-30-2">1989</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met1" novelty="None" advantage="None"/></s>
        <s sid="54">The gavage doses were formulated daily in corn oil.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp15" novelty="None" advantage="None"/></s>
        <s sid="55">The concentrations of the trihalomethanes in the drinking water were chosen as approximately 75% saturation.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp16" novelty="None" advantage="None"/></s>
        <s sid="56">Drinking water formulations were prepared every 3 days with deionized water and given to the mice in measured 200 ml aliquots so that consumption could be determined at each change of the water.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp17" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-10">
        <s sid="57">The mice were sacrificed by carbon dioxide asphyxiation.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp18" novelty="None" advantage="None"/></s>
        <s sid="58">Body and liver weights were obtained.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp19" novelty="None" advantage="None"/></s>
        <s sid="59">For consistency, pieces of the left liver lobe were fixed in buffered formalin for 24 h, transferred to 70% ethanol, processed, and embedded in paraffin for hemotoxylin and eosin staining and immunohistochemical analysis for the proliferating cell nuclear antigen (PCNA).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp20" novelty="None" advantage="None"/></s>
        <s sid="60">The remaining liver was immediately frozen in liquid nitrogen and stored at &#8211;70&#176;C.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp21" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Toxicity.</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-11">
        <s sid="61">Hemotoxylin and eosin-stained sections of liver were evaluated for toxicity using the semi-quantitative procedure described by Iijima et al. (1983), which was modified to incorporate a 0 to +4 grading of severity.<CoreSc1 atype="GSC" type="Met" conceptID="Met2" novelty="None" advantage="None"/></s>
        <s sid="62">Grade 1 consisted of mid lobular ballooning hepatocytes, Grade 2 of the mid lobular ballooning hepatocytes extending to the central vein, Grade 3 of centrilobular necrosis with ballooning hepatocytes, and Grade 4 of necrosis extending from the central vein to the mid lobule zone.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj4" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">PCNA-labeling index.</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-12">
        <s sid="63">Paraffin sections were hydrated and placed in 2N HCl at 50&#176;C for 20 min.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp22" novelty="None" advantage="None"/></s>
        <s sid="64">Endogenous peroxidase was quenched with 0.3% hydrogen peroxide for 30 min.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp23" novelty="None" advantage="None"/></s>
        <s sid="65">The sections were blocked with diluted horse serum for 20 min and incubated with 100 &#956;l monoclonal mouse anti-PCNA (1:300) at 4&#176;C overnight.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp24" novelty="None" advantage="None"/></s>
        <s sid="66">They were then washed and incubated with biotinylated anti-mouse IgG for 30 min at room temperature, followed by a 30-min incubation with Vectastain ABC reagent.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp25" novelty="None" advantage="None"/></s>
        <s sid="67">Stain was developed using 3&#8211;3&#8242;-Diaminobenzidine followed by washing with deionized water and counter staining with hemotoxylin.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp26" novelty="None" advantage="None"/></s>
        <s sid="68">The nuclei of PCNA-positive cells stained brown, while unlabeled nuclei were light blue.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac21" novelty="None" advantage="None"/></s>
        <s sid="69">Approximately 1000 hepatocytes/mouse were evaluated and the PCNA-LI was determined to be the number of PCNA-positive cells divided by the total number of hepatocytes evaluated &#215; 100.<CoreSc1 atype="GSC" type="Met" conceptID="Met3" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Methylation of DNA.</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-13">
        <s sid="70">Liver tissue was homogenized in 0.75 ml TE buffer (10 mM Tris&#8211;HCl, pH 8.0, 0.1 M EDTA) containing 0.5% SDS, and the DNA isolated as previously described (<xref class="xref-bibr" href="#ref-44" rid="xref-ref-44-2">Tao et al., 1998</xref>).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp27" novelty="None" advantage="None"/></s>
        <s sid="71">Briefly, the homogenate was treated with DNase-free RNase (400 &#956;g/ml) and proteinase K (200 &#956;g/ml) and then extracted 3 times with phenol, once with phenol:chloroform (1:1), and finally with chloroform.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp28" novelty="None" advantage="None"/></s>
        <s sid="72">The DNA was precipitated with cold ethanol containing 10 M ammonium acetate (10% volume), washed twice with 70% ethanol, and hydrolyzed in 100 &#956;l of 12 M perchloric acid at 100&#176;C for 1 h.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp29" novelty="None" advantage="None"/></s>
        <s sid="73">After the addition of 230 &#956;l of 6 M KOH, the precipitate was removed by centrifugation.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp30" novelty="None" advantage="None"/></s>
        <s sid="74">The supernatant filtered through a 0.2 &#956;m polypropylene syringe filter (Whatman Inc., Clifton, NJ) and analyzed using a Waters Model 510 HPLC system (Milford, MA) equipped with a Whatman Partisphere C<sub>18</sub> column (4.6 &#215; 250mm, 5 &#956;m particle).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp31" novelty="None" advantage="None"/></s>
        <s sid="75">The column was eluted for 15 min with an isocratic mobile phase of 100 mM ammonium acetate (pH 4.25) containing 0.5% acetonitrile.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp32" novelty="None" advantage="None"/></s>
        <s sid="76">The flow rate was 2 ml/min and the detection wavelength was 280 nm.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp33" novelty="None" advantage="None"/></s>
        <s sid="77">The retention time for cytosine, 5-MeC and guanine were 5.0, 6.5, and 7.4 min, respectively, with thymine and adenine eluted later.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp34" novelty="None" advantage="None"/></s>
        <s sid="78">The percentage of cytosine present as 5-MeC was calculated from the peak areas using the formula, 5-MeC/(5-MeC + cytosine) &#215; 100.<CoreSc1 atype="GSC" type="Met" conceptID="Met4" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Methylation of the promoter region of the c-myc gene.</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-14">
        <s sid="79">The methylation of the promoter region of the c-myc gene was evaluated using Hpa II restriction enzyme digestion followed by Southern blot analysis, as previously described (<xref class="xref-bibr" href="#ref-45" rid="xref-ref-45-3">Tao et al., 1999</xref>Tao et al., 2000).<CoreSc1 atype="GSC" type="Met" conceptID="Met5" novelty="None" advantage="None"/></s>
        <s sid="80">Briefly, isolated DNA was dissolved in TE buffer and digested overnight with Hpa II (10 U/&#956;g DNA) at 37&#176;C.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp35" novelty="None" advantage="None"/></s>
        <s sid="81">Hpa II does not cut CCGG sites when the internal cytosine is methylated.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac22" novelty="None" advantage="None"/></s>
        <s sid="82">The digested DNA was electrophoresed on a 1% agarose gel.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp36" novelty="None" advantage="None"/></s>
        <s sid="83">Equal loading of the gel was indicated by equal ethidium bromide fluorescence.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp37" novelty="None" advantage="None"/></s>
        <s sid="84">The gels were washed with 2X SSC and transferred to Hybond&#8482;-N<sup>+</sup> nylon membranes using a Model 785 vacuum blotter (Bio Rad Laboratories, Hercules, CA).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp38" novelty="None" advantage="None"/></s>
        <s sid="85">The DNA was cross-linked by ultraviolet irradiation (UV Stratalinker Model 2400, Strategene, La Jolla, CA).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp39" novelty="None" advantage="None"/></s>
        <s sid="86">The membranes were pre-hybridized at 42&#176;C for 1 h in 20 ml of pre-hybridization solution (50% formamide, 5X Dehardt's Reagent, 6X SSPE, 10% dextran sulfate, 1% SDS, and 100 &#956;g/ml denatured nonhomologous DNA).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp40" novelty="None" advantage="None"/></s>
        <s sid="87">Random <sup>32</sup>P-labeled c-myc probe (65 &#956;g) was added to the pre-hybridization solution and hybridization continued for 12 h at 42&#176;C.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp41" novelty="None" advantage="None"/></s>
        <s sid="88">After hybridization, the membranes at 20-min intervals were stringently washed 5 times with 4X SSC containing 0.5% SDS at 65&#176;C, 3 times with 2X SSC containing 0.5% SDS at 37&#176;C, and finally once with 2X SSC at 37&#176;C.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp42" novelty="None" advantage="None"/></s>
        <s sid="89">The membranes were dried, sealed in plastic bags, and autoradiography-processed at &#8211;70&#176;C with Kodak Biomax MR X-ray film, Kodak intensifying screens, and a Kodak M35A automatic film processor.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp43" novelty="None" advantage="None"/></s>
        <s sid="90">Optical density of the autoradiograms was measured with a Scion Image Analysis System (Scion Corp., Frederick, MD).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp44" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-15">
        <s sid="91">The c-myc probe was designed from the GeneBank database (GeneBank accession number, M1234) to contain the 1&#8211;1315 bp in the promoter region of the gene.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp45" novelty="None" advantage="None"/></s>
        <s sid="92">The probe was produced by PCR amplification of mouse liver DNA using sense 5&#8242;-TCTAGAACCAATGCACAGAGCAAAAG-3&#8242; and antisense 5&#8242;-GCCTCAGCCCGCAGTCCAGTACTCC-3&#8242; primers.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp46" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Statistical evaluation.</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-16">
        <s sid="93">Statistical analysis was performed using SigmaStat software version 2.03 (Jandel Corp., San Rafeal, CA).<CoreSc1 atype="GSC" type="Met" conceptID="Met6" novelty="None" advantage="None"/></s>
        <s sid="94">Body and organ weights, liver:bw ratio, liver toxicity, PCNA-LI, and DNA methylation were analyzed for statistical significance by an ANOVA followed by a Tukey or Dunnett's test with a p-value &lt; 0.05.<CoreSc1 atype="GSC" type="Met" conceptID="Met7" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>RESULTS</TITLE>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Liver Weight and Toxicity</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-17">
        <s sid="95">When administered by gavage, the trihalomethanes caused dose-dependent increases in the liver:bw ratio (Fig. 1).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs1" novelty="None" advantage="None"/></s>
        <s sid="96">The order of efficacy was chlorodibromomethane &gt; bromodichloromethane &gt; chloroform &gt; bromoform.<CoreSc1 atype="GSC" type="Res" conceptID="Res9" novelty="None" advantage="None"/></s>
        <s sid="97">When administered in drinking water, only chloroform significantly increased the liver:bw ratio (Fig. 2).<CoreSc1 atype="GSC" type="Res" conceptID="Res10" novelty="None" advantage="None"/></s>
        <s sid="98">Even though chloroform administered in drinking water resulted in a daily dose that was greater than the high-dose gavage (i.e., 2.83 and 2.18 mmol/kg, respectively), the increase in the liver:bw ratio was only similar to the low-dose gavage.<CoreSc1 atype="GSC" type="Res" conceptID="Res11" novelty="None" advantage="None"/></s>
        <s sid="99">Furthermore, the other trihalomethanes did not increase the liver:bw ratio, although the daily dose resulting from the drinking water exposure was at least equal to the low-dose gavage that significantly increased the ratio.<CoreSc1 atype="GSC" type="Res" conceptID="Res12" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-18">
        <s sid="100">All 4 trihalomethanes were toxic to the liver; however, the toxicity of bromodichloromethane was different from the other 3.<CoreSc1 atype="GSC" type="Res" conceptID="Res13" novelty="None" advantage="None"/></s>
        <s sid="101">Thus, chloroform, chlorodibromomethane, and bromoform produced liver toxicity that progressed from mid-lobular ballooning hepatocytes to necrosis extending from the central vein to the mid lobular zone, i.e., Grades 1&#8211;4, as described in Material and Methods.<CoreSc1 atype="GSC" type="Res" conceptID="Res14" novelty="None" advantage="None"/></s>
        <s sid="102">In contrast, the low dose of bromodichloromethane induced hydropic degeneration bridging between the central veins, and the high dose-induced necrosis and fibrosis with calcification and giant-cell reaction bridging between the central veins (Fig. 3).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs2" novelty="None" advantage="None"/></s>
        <s sid="103">NTP (1987) has reported that a low dose of bromodichloromethane induced degeneration and a higher dose induced necrosis, fibrosis, and microgranul-omas at the central vein.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac23" novelty="None" advantage="None"/></s>
        <s sid="104">The 2 dose levels of the NTP (1987) study were similar to those used in our study.<CoreSc1 atype="GSC" type="Met" conceptID="Met8" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-19">
        <s sid="105">The relative toxicity of the 3 other trihalomethanes is presented in Figure 4, using the 1&#8211;4 grading system.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs3" novelty="None" advantage="None"/></s>
        <s sid="106">Bromodichloromethane is not included because of the different pathogenesis of its hepatotoxicity.<CoreSc1 atype="GSC" type="Res" conceptID="Res15" novelty="None" advantage="None"/></s>
        <s sid="107">The toxicity of the low dose of the 3 trihalomethanes consisted of mainly mid-lobular ballooning hepatocytes (Grade 1).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs4" novelty="None" advantage="None"/></s>
        <s sid="108">The high doses of chlorodibromomethane and bromoform resulted in mid- lobular ballooning hepatocytes extending to the central vein (Grade 2), and the high dose of chloroform resulted in necrosis at the central vein (Grades 3 and 4).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs5" novelty="None" advantage="None"/></s>
        <s sid="109">Hence, necrosis was apparent only in mice administered the high dose of chloroform and bromodichloromethane, so that these 2 trihalomethanes were more toxic than chlorodibromomethane and bromoform.<CoreSc1 atype="GSC" type="Res" conceptID="Res16" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-20">
        <s sid="110">The toxicity resulting from the 3 trihalomethanes other than bromodichloromethane, when administered in the drinking water, is also presented in Figure 4.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs6" novelty="None" advantage="None"/></s>
        <s sid="111">The toxicity of chlorodibromomethane and bromoform administered in drinking water did not differ from the low-dose gavage.<CoreSc1 atype="GSC" type="Res" conceptID="Res17" novelty="None" advantage="None"/></s>
        <s sid="112">Although the daily dose resulting from chloroform administered in drinking water was greater than the high-dose gavage, it was less toxic than even the low-dose gavage.<CoreSc1 atype="GSC" type="Res" conceptID="Res18" novelty="None" advantage="None"/></s>
        <s sid="113">The toxicity of bromodichloromethane administered in drinking water was similar to the low-dose gavage, inducing hydropic degeneration at the central vein that in some cases was bridging between central veins.<CoreSc1 atype="GSC" type="Res" conceptID="Res19" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">PCNA-LI</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-21">
        <s sid="114">The trihalomethanes, when administered by gavage, caused a dose-dependent increase in the PCNA-LI (Fig. 5).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs7" novelty="None" advantage="None"/></s>
        <s sid="115">The high-dose level of chloroform and bromoform resulted in the greatest increase in the PCNA-LI, followed by bromodichloromethane and chlorodibromomethane.<CoreSc1 atype="GSC" type="Res" conceptID="Res20" novelty="None" advantage="None"/></s>
        <s sid="116">The low-dose gavage of the trihalomethanes, with the exception of chloroform, also increased the PCNA-LI.<CoreSc1 atype="GSC" type="Res" conceptID="Res21" novelty="None" advantage="None"/></s>
        <s sid="117">When administered in drinking water, the trihalomethanes increased the PCNA-LI to an extent similar to their low gavage dose (Fig. 6).<CoreSc1 atype="GSC" type="Res" conceptID="Res22" novelty="None" advantage="None"/></s>
        <s sid="118">However, the increase was only statistically significant for chloroform and bromoform.<CoreSc1 atype="GSC" type="Res" conceptID="Res23" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Methylation of DNA and the c-myc Gene</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-22">
        <s sid="119">Before determining whether the trihalomethanes decreased the methylation of the c-myc gene, the ability of the high gavage dose of chloroform and bromodichloromethane to decrease global DNA methylation was determined.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj5" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Hyp" conceptID="Hyp4" novelty="None" advantage="None"/></s>
        <s sid="120">Both trihalomethanes decreased global DNA methylation by about 40% (Fig. 7).<CoreSc1 atype="GSC" type="Res" conceptID="Res24" novelty="None" advantage="None"/></s>
        <s sid="121">Since 2 trihalomethanes demonstrated the ability to decrease DNA methylation, it seemed reasonable to determine the ability of the trihalomethanes to decrease the methylation of a specific gene, i.e., the promoter region for the c-myc gene.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa1" novelty="None" advantage="None"/></s>
        <s sid="122">Southern blots of Hpa II-digested liver DNA from mice administered the trihalomethanes contained bands of 2.7, 2.2, 1.0, 0.5, and 0.2 Kb when probed for the c-myc promoter region (Figs. 8 and 9).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs8" novelty="None" advantage="None"/></s>
        <s sid="123">These bands were absent when the DNA was not digested with Hpa II and when DNA isolated from vehicle (corn oil and drinking water) control mice was digested with Hpa II.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs9" novelty="None" advantage="None"/></s>
        <s sid="124">Thus, in vehicle control animals the internal cytosine of CCGG sites appears to be methylated, thereby preventing digestion by Hpa II.<CoreSc1 atype="GSC" type="Res" conceptID="Res25" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-23">
        <s sid="125">To demonstrate that the bands present in Hpa II digested DNA from trihalomethane-treated mice resulted from decreased methylation at CCGG sites, DNA was digested with Msp I. Msp I cuts DNA irrespective of the methylation status of the internal C of CCGG sites.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa2" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Met" conceptID="Met9" novelty="None" advantage="None"/></s>
        <s sid="126">Msp I-digested liver DNA from control mice, when probed for c-myc, resulted in a smear of radioactivity in the 100&#8211;600 bp range (data not presented).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs10" novelty="None" advantage="None"/></s>
        <s sid="127">This smear of radioactivity is likely the result of cuts at the 12 CCGG sites in the area probed.<CoreSc1 atype="GSC" type="Res" conceptID="Res26" novelty="None" advantage="None"/></s>
        <s sid="128">Since the smear of radioactivity was not present after the DNA was digested with Hpa II, these sites must be methylated in control mice.<CoreSc1 atype="GSC" type="Res" conceptID="Res27" novelty="None" advantage="None"/></s>
        <s sid="129">Furthermore, the 2.7- and 2.2-Kb bands were demonstrated to result from Hpa II cutting of the DNA at a CCGG site in the promoter region and at a site downstream from the probe.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs11" novelty="None" advantage="None"/></s>
        <s sid="130">When DNA from trihalomethane-treated mice was digested with both Hpa II and Eco0109 I, the larger bands were lost with the appearance of a 0.7-Kb band.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs12" novelty="None" advantage="None"/></s>
        <s sid="131">Eco0109 I is a methylation-insensitive restriction enzyme that cuts PuGGNCCPy sites between the GG.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj6" novelty="None" advantage="None"/></s>
        <s sid="132">The 0.7-Kb band corresponded to the distance between a CCGG site and the Eco 0109 I site in the promoter region.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj7" novelty="None" advantage="None"/></s>
        <s sid="133">Thus, 0.7 Kb of the larger bands was demonstrated to be within the promoter region of the c-myc gene, with the rest of the band downstream from the Eco 0109 I site.<CoreSc1 atype="GSC" type="Res" conceptID="Res28" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-24">
        <s sid="134">The intensity of the bands present after Hpa II digestion was determined using a Scion Image Analysis System (Scion Corp., Frederick, MD).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp47" novelty="None" advantage="None"/></s>
        <s sid="135">Methylation of the c-myc promoter decreased with the increasing dose of the trihalomethane administered by gavage.<CoreSc1 atype="GSC" type="Res" conceptID="Res29" novelty="None" advantage="None"/></s>
        <s sid="136">The 5 bands after Hpa II digestion exhibited similar dose-response curves.<CoreSc1 atype="GSC" type="Res" conceptID="Res30" novelty="None" advantage="None"/></s>
        <s sid="137">Therefore, Figure 10 contains the dose-response curves for band 3 (1.0Kb), chosen as representative since it is the middle band in size and the second darkest in intensity.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs13" novelty="None" advantage="None"/></s>
        <s sid="138">The dose-response curves for chloroform and bromodichloromethane increased sharply between the low- and high-dose levels, while the relationships for bromoform and chlorodibromomethane appeared convex.<CoreSc1 atype="GSC" type="Res" conceptID="Res31" novelty="None" advantage="None"/></s>
        <s sid="139">Furthermore, chloroform and bromodichloromethane reduced the methylation of the c-myc gene more than the 2 other trihalomethanes.<CoreSc1 atype="GSC" type="Res" conceptID="Res32" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-25">
        <s sid="140">The intensities of the 5 bands after Hpa II digestion of DNA from mice administered the trihalomethanes in drinking water were compared, using the equivalent mmol/kg body weight dose to the dose-response relationship obtained when they were administered by gavage.<CoreSc1 atype="GSC" type="Met" conceptID="Met10" novelty="None" advantage="None"/></s>
        <s sid="141">Because similar results were obtained for the 5 bands, only the comparison for band 3 is presented (Fig. 10).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs14" novelty="None" advantage="None"/></s>
        <s sid="142">The intensity of band 3 from mice exposed via their drinking water to the trihalomethanes, except for chloroform, was not different from that predicted by the dose-response relationship.<CoreSc1 atype="GSC" type="Res" conceptID="Res33" novelty="None" advantage="None"/></s>
        <s sid="143">In contrast, the intensity of band 3 resulting from chloroform was much less than predicted.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs15" novelty="None" advantage="None"/></s>
        <s sid="144">The 4 other bands in Hpa II-digested DNA from mice administered chloroform in drinking water also had intensities that were, at most, similar to the low gavage dose (data not presented).<CoreSc1 atype="GSC" type="Res" conceptID="Res34" novelty="None" advantage="None"/></s>
        <s sid="145">Hence, although the dose resulting from chloroform in drinking water was greater than the high gavage dose, the intensity of the Hpa II digestion bands were, at most, similar to the low gavage dose.<CoreSc1 atype="GSC" type="Res" conceptID="Res35" novelty="None" advantage="None"/></s>
        <s sid="146">Thus, chloroform administered in drinking water had much less effect than when administered by gavage.<CoreSc1 atype="GSC" type="Res" conceptID="Res36" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>DISCUSSION</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-26">
        <s sid="147">The trihalomethanes are found in finished drinking water as by-products of chlorination (<xref class="xref-bibr" href="#ref-48" rid="xref-ref-48-2">Uden and Miller, 1983</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac24" novelty="None" advantage="None"/></s>
        <s sid="148">The U.S. Environmental Protection Agency (1979, 1994) has set a standard for trihalomethanes in drinking water, in part because of their carcinogenic activity in laboratory animals, including liver cancer in female B6C3F1 mice (<xref class="xref-bibr" href="#ref-27" rid="xref-ref-27-3">NCI, 1976</xref>; <xref class="xref-bibr" href="#ref-28" rid="xref-ref-28-3">NTP, 1985</xref>, <xref class="xref-bibr" href="#ref-29" rid="xref-ref-29-3">1987</xref>, <xref class="xref-bibr" href="#ref-30" rid="xref-ref-30-3">1989</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac25" novelty="None" advantage="None"/></s>
        <s sid="149">However, the relevance to humans of the carcinogenic activity in mouse liver of the trihalomethanes, especially for chloroform, has been questioned (<xref class="xref-bibr" href="#ref-37" rid="xref-ref-37-2">Pohl et al., 1979</xref>; U.S. EPA, 1979; <xref class="xref-bibr" href="#ref-40" rid="xref-ref-40-2">Reitz et al., 1990</xref>).<CoreSc1 atype="GSC" type="Mot" conceptID="Mot2" novelty="None" advantage="None"/></s>
        <s sid="150">It was argued that the very weak genotoxic activity of chloroform indicates a nongenotoxic mechanism resulting from regenerative hyperplasia in response to toxicity (<xref class="xref-bibr" href="#ref-5" rid="xref-ref-5-2">Butterworth et al., 1992</xref>; <xref class="xref-bibr" href="#ref-40" rid="xref-ref-40-3">Reitz et al., 1990</xref>; <xref class="xref-bibr" href="#ref-42" rid="xref-ref-42-2">Rosenthal, 1987</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac26" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-27">
        <s sid="151">Toxicity, cell proliferation, and DNA methylation are all possible components of a nongenotoxic mechanism for the trihalomethanes.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac27" novelty="None" advantage="None"/></s>
        <s sid="152">DNA methylation can control the expression of genes including those associated with cell proliferation.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac28" novelty="None" advantage="None"/></s>
        <s sid="153">The expression of c-myc has been reported to be increased by chloroform administered by gavage to B6C3F1 mice (<xref class="xref-bibr" href="#ref-43" rid="xref-ref-43-2">Sprankle et al., 1996</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac29" novelty="None" advantage="None"/></s>
        <s sid="154">We have also found increased expression of c-myc in mice administered chloroform by gavage as well as in the drinking water (data not presented).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs16" novelty="None" advantage="None"/></s>
        <s sid="155">Chloroform also increased the expression of c-fos (<xref class="xref-bibr" href="#ref-43" rid="xref-ref-43-3">Sprankle et al., 1996</xref>) and 4 genes identified by the differential-display technique (<xref class="xref-bibr" href="#ref-21" rid="xref-ref-21-1">Kegelmeyer et al., 1997</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac30" novelty="None" advantage="None"/></s>
        <s sid="156">These genes could also be hypomethylated, as suggested by the significant decrease (&#8764;40%) in global DNA methylation, indicating that many genes besides c-myc are hypomethylated.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp5" novelty="None" advantage="None"/></s>
        <s sid="157">Thus, the hypomethylation of c-myc could be an indicator of possible hypomethylation of other genes.<CoreSc1 atype="GSC" type="Con" conceptID="Con4" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-28">
        <s sid="158">A possible mechanism for DNA hypomethylation by the trihalomethanes is to prevent, after DNA replication, the methylation of the daughter strands of DNA.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp6" novelty="None" advantage="None"/></s>
        <s sid="159">Under normal conditions, there is very little cell proliferation in the liver.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac31" novelty="None" advantage="None"/></s>
        <s sid="160">Therefore, this mechanism requires that the trihalomethanes enhance cell proliferation in order to produce unmethylated daughter strands of DNA.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp7" novelty="None" advantage="None"/></s>
        <s sid="161">All four trihalomethanes did enhance cell proliferation.<CoreSc1 atype="GSC" type="Res" conceptID="Res37" novelty="None" advantage="None"/></s>
        <s sid="162">The trihalomethanes could then prevent the methylation of the daughter strands of DNA by inhibiting DNA methyltransferase (DNA MTase) or by reducing the availability of S-adenosyl methionine (SAM).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac32" novelty="None" advantage="None"/></s>
        <s sid="163">DNA MTase activity is increased in most tumors, including liver tumors, in the presence of DNA hypomethylation (<xref class="xref-bibr" href="#ref-2" rid="xref-ref-2-3">Baylin et al., 1998</xref>; Bird et al., 1996; <xref class="xref-bibr" href="#ref-18" rid="xref-ref-18-2">Jones and Buckley, 1990</xref>; <xref class="xref-bibr" href="#ref-52" rid="xref-ref-52-2">Wolffe et al., 1999</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac33" novelty="None" advantage="None"/></s>
        <s sid="164">Also dichloroacetic acid and trichloroacetic acids in mouse liver decreased the methylation of the c-myc gene without decreasing DNA MTase activity (<xref class="xref-bibr" href="#ref-47" rid="xref-ref-47-1">Tao et al., 2000b</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac34" novelty="None" advantage="None"/></s>
        <s sid="165">Therefore, it is unlikely that decreased activity of DNA MTase is the mechanism for DNA hypomethylation.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac35" novelty="None" advantage="None"/></s>
        <s sid="166">The level of SAM could be reduced by liver toxicity that reduces the level of ATP required for the synthesis of SAM or by reducing the level of GSH as proposed by Lertratanangkoon et al. (1997).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac36" novelty="None" advantage="None"/></s>
        <s sid="167">Depletion of GSH induces its synthesis, utilizing SAM for the synthesis of cysteine.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac37" novelty="None" advantage="None"/></s>
        <s sid="168">The prevention of dichloroacetic acid- and trichloroacetic acid-induced hypomethylation of c-jun and c-myc genes by methionine supports this hypothesis (<xref class="xref-bibr" href="#ref-46" rid="xref-ref-46-1">Tao et al., 2000a</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac38" novelty="None" advantage="None"/></s>
        <s sid="169">Presumably, methionine prevented the decrease in methylation by maintaining the availability of SAM.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac39" novelty="None" advantage="None"/></s>
        <s sid="170">Hence, it is proposed that the trihalomethanes decreased DNA methylation by enhancing cell proliferation, possibly as a regenerative response to their toxicity, and then preventing the methylation of the newly synthesized daughter strands of DNA.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp8" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-29">
        <s sid="171">All four trihalomethanes were toxic to the liver.<CoreSc1 atype="GSC" type="Res" conceptID="Res38" novelty="None" advantage="None"/></s>
        <s sid="172">The toxicity of the trihalomethanes, except for bromodichloromethane, started with ballooning hepatocytes in the mid-zone of the lobule and progressed to centrilobular necrosis.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs17" novelty="None" advantage="None"/></s>
        <s sid="173">However, in contrast to the other trihalomethanes, the toxicity induced by bromodichloromethane was mainly confined to the central lobular zone and included hydropic degeneration that progressed to centrilobular bridging necrosis, fibrosis and calcification.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs18" novelty="None" advantage="None"/></s>
        <s sid="174">Similar toxicity for bromodichloromethane has been reported by NTP (1987); the low dose used in their bioassay resulted in degeneration, and the high dose resulted in necrosis, fibrosis, and the presence of microgranulomas at the central vein.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac40" novelty="None" advantage="None"/></s>
        <s sid="175">The two dose levels of their bioassay were similar to those reported here.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac41" novelty="None" advantage="None"/></s>
        <s sid="176">Bromodichloromethane has also been reported to differ from the other trihalomethanes by demonstrating mutagenic activity that required activation with GSH (<xref class="xref-bibr" href="#ref-33" rid="xref-ref-33-2">Pegram et al., 1997</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac42" novelty="None" advantage="None"/></s>
        <s sid="177">Thus, the genotoxicity and toxicity of bromodichloromethane distinguishes it from the other trihalomethanes.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac43" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-30">
        <s sid="178">Comparison of the toxicity of the trihalomethanes to their ability to enhance cell proliferation indicated a lack of correlation.<CoreSc1 atype="GSC" type="Res" conceptID="Res39" novelty="None" advantage="None"/></s>
        <s sid="179">All four trihalomethanes, when administered by gavage, increased the liver:bw ratio, induced liver toxicity, and enhanced cell proliferation, i.e., the PCNA-LI.<CoreSc1 atype="GSC" type="Res" conceptID="Res40" novelty="None" advantage="None"/></s>
        <s sid="180">Bromodichloromethane and chloroform were more toxic than chlorodibromomethane and bromoform.<CoreSc1 atype="GSC" type="Res" conceptID="Res41" novelty="None" advantage="None"/></s>
        <s sid="181">However, chlorodibromomethane was the most potent in increasing the liver:bw ratio followed by bromodichloromethane &gt; chloroform &gt; bromoform.<CoreSc1 atype="GSC" type="Res" conceptID="Res42" novelty="None" advantage="None"/></s>
        <s sid="182">With respect to the PCNA-LI, chloroform and bromoform were the most efficacious.<CoreSc1 atype="GSC" type="Res" conceptID="Res43" novelty="None" advantage="None"/></s>
        <s sid="183">Thus, the high dose of bromoform increased the PCNA-LI similarly to the high dose of chloroform although, of the four trihalomethanes, it was the weakest in increasing the liver:bw ratio and inducing toxicity.<CoreSc1 atype="GSC" type="Res" conceptID="Res44" novelty="None" advantage="None"/></s>
        <s sid="184">Although both the high dose of bromoform and the low dose of chloroform were minimally toxic (Grade &#8764;1.5), only bromoform increased the PCNA-LI, i.e., 25.3 &#177; 2.2 and 0.87 &#177; 0.22 for the high dose of bromoform and the low dose of chloroform, respectively.<CoreSc1 atype="GSC" type="Res" conceptID="Res45" novelty="None" advantage="None"/></s>
        <s sid="185">Thus, the ability of a trihalomethane to increase cell proliferation did not correlate with its toxicity.<CoreSc1 atype="GSC" type="Res" conceptID="Res46" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-31">
        <s sid="186">The effect of the trihalomethanes on the PCNA-LI also did not correlate with their effect on the liver:bw ratio.<CoreSc1 atype="GSC" type="Res" conceptID="Res47" novelty="None" advantage="None"/></s>
        <s sid="187">The large increase in the PCNA-LI induced by bromoform did not correlate with its limited increase in the liver/bw ratio, which could be due to its very weak toxicity, i.e. inducing only mid-zonal ballooning hepatocytes.<CoreSc1 atype="GSC" type="Res" conceptID="Res48" novelty="None" advantage="None"/></s>
        <s sid="188">In contrast, along with their enhancement of cell proliferation, the more extensive toxicity of chloroform and bromodichloromethane could contribute to their greater increase in the liver:bw ratio.<CoreSc1 atype="GSC" type="Res" conceptID="Res49" novelty="None" advantage="None"/></s>
        <s sid="189">Furthermore, the extensive toxicity of chloroform and bromodichloromethane is consistent with their enhancement of cell proliferation resulting from regenerative hyperplasia, while the minimal toxicity of bromoform and chlorodibromomethane indicate that they increase cell proliferation by another mechanism.<CoreSc1 atype="GSC" type="Res" conceptID="Res50" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-32">
        <s sid="190">For the most part, the dose-response relationships for the increase in the PCNA-LI and the decrease in the methylation of the c-myc gene by the trihalomethanes were similar.<CoreSc1 atype="GSC" type="Res" conceptID="Res51" novelty="None" advantage="None"/></s>
        <s sid="191">The PCNA-LI increased sharply between the low and high doses of chloroform, bromodichloromethane, and bromoform with the dose-response curve for chloroform suggesting a threshold.<CoreSc1 atype="GSC" type="Res" conceptID="Res52" novelty="None" advantage="None"/></s>
        <s sid="192">The dose-response curves for the ability of chloroform and bromodichloromethane to reduce the methylation of the c-myc gene also increased sharply with dose.<CoreSc1 atype="GSC" type="Res" conceptID="Res53" novelty="None" advantage="None"/></s>
        <s sid="193">Thus, the dose-response curves for the enhancement of the PCNA-LI and for the reduction in the methylation of the c-myc gene suggested that chloroform and bromodichloromethane have to overcome detoxifying mechanisms prior to exerting full activity.<CoreSc1 atype="GSC" type="Res" conceptID="Res54" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-33">
        <s sid="194">Chloroform administered in drinking water affected the liver:bw ratio, toxicity, cell proliferation, and methylation of the c-myc gene much less than when administered by gavage.<CoreSc1 atype="GSC" type="Res" conceptID="Res55" novelty="None" advantage="None"/></s>
        <s sid="195">The daily dose of chloroform administered in drinking water was greater than its high gavage-dose.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp48" novelty="None" advantage="None"/></s>
        <s sid="196">Furthermore, drinking water exposure was for seven days a week, while gavage treatment was only five days a week.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp49" novelty="None" advantage="None"/></s>
        <s sid="197">Still, the ability of chloroform in drinking water to increase the liver:bw ratio, induce toxicity, increase the PCNA-LI, and reduce the methylation of the c-myc gene was at most only as efficacious as its low gavage dose.<CoreSc1 atype="GSC" type="Res" conceptID="Res56" novelty="None" advantage="None"/></s>
        <s sid="198">This is consistent with the previously reported weaker ability of chloroform administered in the drinking water to induce toxicity and to enhance cell proliferation, compared to chloroform administered by oral gavage (<xref class="xref-bibr" href="#ref-23" rid="xref-ref-23-2">Larson et al., 1994</xref>; <xref class="xref-bibr" href="#ref-34" rid="xref-ref-34-2">Pereira, 1994</xref>; <xref class="xref-bibr" href="#ref-35" rid="xref-ref-35-2">Pereira and Grothaus, 1997</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res57" novelty="None" advantage="None"/></s>
        <s sid="199">It was also consistent with the inability of chloroform to promote liver tumors in mice when administered in drinking water at daily dose levels similar to its carcinogenic dose when administered by gavage (<xref class="xref-bibr" href="#ref-19" rid="xref-ref-19-2">Jorgenson et al., 1985</xref>; <xref class="xref-bibr" href="#ref-20" rid="xref-ref-20-2">Klaunig et al., 1986</xref>, <xref class="xref-bibr" href="#ref-36" rid="xref-ref-36-2">Pereira et al., 1985</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res58" novelty="None" advantage="None"/></s>
        <s sid="200">The weaker activity of chloroform administered in drinking water could result from its incremental delivery each time the mouse drinks, which should result in a lower liver concentration than obtained from the bolus delivered by oral gavage.<CoreSc1 atype="GSC" type="Con" conceptID="Con5" novelty="None" advantage="None"/></s>
        <s sid="201">The lower liver concentration of chloroform could be insufficient to overcome GSH and other detoxification mechanisms.<CoreSc1 atype="GSC" type="Con" conceptID="Con6" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-34">
        <s sid="202">Drinking water exposure to the other three trihalomethanes resulted in daily dose levels that were similar to or slightly higher than the low dose administered by oral gavage (the greatest difference was for bromoform, i.e., 1.19 and 0.79 mmol/kg/day by drinking water and gavage, respectively).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp50" novelty="None" advantage="None"/></s>
        <s sid="203">Drinking water exposure affected liver:bw ratio, liver toxicity, PCNA-LI, and c-myc methylation, to a degree similar for the most part to their low gavage dose.<CoreSc1 atype="GSC" type="Res" conceptID="Res59" novelty="None" advantage="None"/></s>
        <s sid="204">However, in contrast to chloroform, the evaluation of the other trihalomethanes in drinking water at concentrations that were equivalent to their high gavage dose was prevented by their limited solubility.<CoreSc1 atype="GSC" type="Res" conceptID="Res60" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-35">
        <s sid="205">In conclusion, the trihalomethanes administered by gavage increased cell proliferation and decreased DNA methylation, supporting a nongenotoxic mechanism for their carcinogenic activity in mouse liver.<CoreSc1 atype="GSC" type="Con" conceptID="Con7" novelty="None" advantage="None"/></s>
        <s sid="206">The dose-response curves of the trihalomethanes, especially chloroform and bromodichloromethane, suggested the need to overcome detoxification mechanisms prior to exerting full activity, which could explain their weak activity, especially that of chloroform, when administered in drinking water.<CoreSc1 atype="GSC" type="Con" conceptID="Con8" novelty="None" advantage="None"/></s>
        <s sid="207">The slower rate of delivery by drinking water is expected to result in a lower liver concentration that should increase the opportunity for detoxification.<CoreSc1 atype="GSC" type="Con" conceptID="Con9" novelty="None" advantage="None"/></s>
        <s sid="208">Hence, the activity of the trihalomethanes appears to be dependent on their rate of delivery, i.e., rapidly by oral gavage and more slowly in drinking water.<CoreSc1 atype="GSC" type="Con" conceptID="Con10" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Footnotes</TITLE>
    </SEC>
    <SEC>
      <TITLE>REFERENCES</TITLE>
    </SEC>
  </BODY>
</PAPER>